Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response

Abdelrahman, Ahmed S.; Ekladious, Mena E.Y.; Badran, Ethar M.; Madkour, Sherihan S

doi:10.1016/j.diii.2022.06.007

Cited by 10 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bartnik et al, found moderate agreement when using computed tomography (Kappa 0.70), especially in the nonviable tumor category (kappa 0.80) [10]. Abdelrahman et al, reported almost perfect interob-Abdelrahman et al, reported almost perfect interob-interobserver agreement for arterial phase hyperenhancement, washout, enhancement similar to pretreatment and DWI findings in all treated HCCs, when using MRI (kappa 0.815, 0.837, 0.826 and 0.81 respectively) [11].…”

Section: Discussionmentioning

confidence: 97%

Double chambered right ventricle with perimembranous defect and severe aortic aneurism: A case in an adult patient

Bartolacelli¹

2022

Open J Clin Med Images

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Double chambered right ventricle with perimembranous defect and severe aortic aneurism: A case in an adult patient

Bartolacelli¹

2022

Open J Clin Med Images

View full text Add to dashboard Cite

show abstract

“…The diagnosis of HCC in this study was based on the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver guidelines 29 , 30 . The main diagnostic criteria in this study were typical imaging (enhanced computerized tomography (CT) and/or magnetic resonance imaging (MRI)) combined with laboratory examinations of alpha-fetoprotein (AFP) levels.…”

Section: Methodsmentioning

confidence: 99%

Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial

Lin,

Wu,

Rao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The purpose of this study was to investigate the relationship between circulating cytokines and liver function and prognosis of patients with advanced hepatocellular carcinoma (HCC) treated with radiotherapy combined with tislelizumab and anlotinib. The liver function indexes and pre-treatment levels of cytokines in 47 patients were measured by chemical method and flow cytometry. The median follow-up was 23.1 months. The objective response and the disease control rates were 46.8% and 68.1%, while overall survival (OS) and progression-free survival (PFS) were 12.6 and 11.4 months, respectively. Adverse events (2.1%) were grade 3–4. In addition to stage, intrahepatic metastasis and Child–Pugh score, pre-treatment interleukin-6 (IL-6) was the main cytokine affecting OS and PFS (p < 0.05). The OS (14.63 pg/mL as cutoff value) and PFS (9.85 pg/mL as cutoff value) of patients with low IL-6 levels exceeded those with high levels (21.0 and 6.9, 15.8 and 10.0 months, respectively). The risks of death and disease progression were reduced by 63.0% (HR = 0.37, 95% CI: 0.19–0.72) and 43.0% (HR = 0.57, 95% CI: 0.22–1.47), respectively. Pre-treatment IL-6 levels may be a simple and effective prognostic indicator for patients with advanced HCC treated with radiotherapy combined with immunotargeted therapy.

show abstract

“…Recent literature reports have shown that the accuracy of HCC diagnosis can be further improved by adding auciliary features such as restricted diffusion, mild-moderate T2 hyperintensity, and hepatobiliary phase hypointensity (10)(11)(12)(13). Among them, benign and malignant lesions in LR-3 classification are not easy to judge, and there are still great challenges whether patients can receive effective clinical treatment (14,15).…”

Section: Introductionmentioning

confidence: 99%

Liver Imaging Reporting and Data System (LI-RADS) v2018: differential diagnostic value of ADC values for benign and malignant nodules with moderate probability (LR-3)

Chen,

Cai,

Xia

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo evaluate the usefulness of the apparent diffusion coefficient (ADC) in differentiating between benign and malignant LR-3 lesions classified by Liver Imaging Reporting and Data System 2018 (LI-RADS v2018).MethodsRetrospectively analyzed 88 patients with liver nodules confirmed by pathology and classified as LR-3 by LI-RADS. All patients underwent preoperative contrast-enhanced MR examination, and the following patient-related imaging features were collected: tumor size,nonrim APHE, nonperipheral “washout”, enhancing “capsule”, mild-moderate T2 hyperintensity, fat in mass, restricted diffusion, and nodule-in-nodule architecture. We performed ROC analysis and calculated the sensitivity and specificity.ResultsA total of 122 lesions were found in 88 patients, with 68 benign and 54 malignant lesions. The mean ADC value for malignant and benign lesions were 1.01 ± 0.15 × 103 mm2/s and 1.41 ± 0.31 × 103 mm2/s, respectively. The ADC value of malignant lesions was significantly lower than that of benign lesions, p < 0.0001. Compared with other imaging features, ADC values had the highest AUC (AUC = 0.909), with a sensitivity of 92.6% and a specificity of 74.1% for the differentiation of benign and malignant lesions.ConclusionsADC values are useful for differentiating between benign and malignant liver nodules in LR-3 classification, it improves the sensitivity of LI-RADS in the diagnosis of HCC while maintaining high specificity, and we recommend including ADC values in the standard interpretation of LI-RADSv2018.

show abstract

Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response

Cited by 10 publications

References 31 publications

Double chambered right ventricle with perimembranous defect and severe aortic aneurism: A case in an adult patient

Double chambered right ventricle with perimembranous defect and severe aortic aneurism: A case in an adult patient

Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial

Liver Imaging Reporting and Data System (LI-RADS) v2018: differential diagnostic value of ADC values for benign and malignant nodules with moderate probability (LR-3)

Contact Info

Product

Resources

About